I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and ...

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, And ...

1 week from now

Aug 28, 2024  · Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short-term investments as of June 30, 2024, and cash runway expected into …

prnewswire.com

I-Mab Reports Third Quarter 2024 Results

1 week from now

3 days ago  · Third Quarter 2024 Financial Results. Cash Position. As of September 30, 2024, the Company had cash and cash equivalents, and short-term investments of $184.4 million, …

i-mabbiopharma.com

I-Mab Reports Third Quarter 2024 Results - Nasdaq

1 week from now

Sep 30, 2024  · (1) Includes share-based compensation expense of $0.6 million and $0.9 million for the three and nine months ended September 30, 2024, respectively, compared to $0.6 …

nasdaq.com

I-Mab Reports Third Quarter 2024 Results - Morningstar

1 week from now

3 days ago  · Third Quarter 2024 Financial Results. Cash Position. As of September 30, 2024, the Company had cash and cash equivalents, and short-term investments of $184.4 million, …

morningstar.com

I-Mab Reports Third Quarter 2024 Results - BioSpace

1 week from now

2 days ago  · Third Quarter 2024 Financial Results. Cash Position. As of September 30, 2024, the Company had cash and cash equivalents, and short-term investments of $184.4 million, …

biospace.com

I-Mab’s Third Quarter Results: Progress In Cancer Immunotherapies

1 week from now

18 hours ago  · Key financial highlights reveal I-Mab’s total cash and short-term investments amounted to $184.4 million as of September 30, 2024, providing a financial runway into 2027.

businessinsider.com

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, And ...

1 week from now

Aug 28, 2024  · Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific) Well-positioned for pipeline advancement with $207.5 million in cash and …

i-mabbiopharma.com

I-Mab Reports Third Quarter 2024 Results - Yahoo Finance

1 week from now

2 days ago  · Third Quarter 2024 Financial Results. Cash Position. As of September 30, 2024, the Company had cash and cash equivalents, and short-term investments of $184.4 million, …

yahoo.com

I-Mab Reports Third Quarter 2024 Results - PR Newswire

1 week from now

2 days ago  · Third Quarter 2024 Financial Results. Cash Position. As of September 30, 2024, the Company had cash and cash equivalents, and short-term investments of $184.4 million, …

prnewswire.com

Invivyd Reports Third Quarter 2024 Financial Results And ... - Nasdaq

1 week from now

2 days ago  · Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with $106.9 million in cash and cash equivalents; Targets near-term (1H 2025) …

nasdaq.com

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, And

1 week from now

Nov 8, 2024  · First-Half 2024 Financial Results. Cash Position. As of June 30, 2024, the Company had cash and cash equivalents, and short-term investments of $207.5 million, compared to …

advfn.com